Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220083 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
A Phase 3 study of Focal Segmental Glomerulosclerosis, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
- 20
- Study locations
NCT07220083 is a Phase 3 study of Focal Segmental Glomerulosclerosis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 286 participants, above the 222-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT07220083, a Phase 3 study of Focal Segmental Glomerulosclerosis, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS. Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BI 764198
Study Locations (20)
California
- West Coast Kidney Institute - Fremont
- Amicis Research Center - Balboa - Granada Hills
- Academic Medical Research Institute - Glendale - Los Angeles
- University of California Los Angeles - Los Angeles
- North America Research Institute - San Dimas
- Kaiser Permanente - French Campus - San Francisco
- Valiance Clinical Research-Tarzana-68237 - Tarzana
- National Institute of Clinical Research - Victorville - Victorville
Florida
- Florida Kidney Physicians - Boca Raton - Boca Raton
- Florida Kidney Physicians, LLC - Fort Lauderdale - Fort Lauderdale
- Total Research Group, LLC - Miami
- CTR Oakwater, LLC - Orlando
- Panoramic Health - Riverview
Georgia
- Emory Children's Center - Atlanta
- Southeast Kidney Associates - East Point - East Point
- Memorial Health University Hospital - Savannah
Alabama
- Alabama Kidney Research - Alabaster
- Apogee Clinical Research - Huntsville
Arizona
- Southwest Kidney Institute - Surprise
Colorado
- Colorado Kidney Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2029-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220083
The ClinicalTrials.gov registry entry for NCT07220083 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 222-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (29% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220083 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07220083 about?
NCT07220083 is a clinical study titled "A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)". This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every parti...
What is the current status of trial NCT07220083?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2026-02-16. Estimated completion is 2029-12-18.
What conditions does trial NCT07220083 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis.
What interventions are being tested in trial NCT07220083?
The interventions under investigation include: Placebo (DRUG), BI 764198 (DRUG).
Who is sponsoring clinical trial NCT07220083?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220083 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
ACTIVE NOT RECRUITING · Phase 3
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
-
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
-
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.